|
Feb 24
|
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
|
|
Feb 20
|
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
|
|
Feb 13
|
atai Life Sciences Announces Pricing of Public Offering of Common Shares
|
|
Feb 12
|
atai Life Sciences Announces Proposed Public Offering of Common Shares
|
|
Dec 30
|
US Penny Stocks To Consider In December 2024
|
|
Aug 7
|
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
|
Jun 26
|
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
|
|
Jun 20
|
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
|
|
May 23
|
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
|
|
May 15
|
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
|
|
Apr 24
|
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
|
|
Apr 17
|
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
|
|
Apr 1
|
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 28
|
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
|
|
Mar 27
|
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
|
|
Mar 12
|
atai Life Sciences advances VLS-01 for treatment-resistant depression
|
|
Mar 4
|
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
|
|
Jan 8
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 5
|
Ecstasy-for-Medicine Advocate Raises $100 Million
|
|
Jan 4
|
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
|